A pilot to assess target engagement of terazosin in Parkinson's disease.

ABSTRACT:

Background

Impaired brain energy metabolism is a key feature of Parkinson's disease (PD). Terazosin (TZ) binds phosphoglycerate kinase 1 and stimulates its activity, which enhances glycolysis and increases ATP levels. Preclinical and epidemiologic data suggest that TZ may be neuroprotective in PD. We aimed to assess target engagement and safety of TZ in people with PD.

Methods

We performed a 12-week pilot study in people with PD. Participants were randomized to receive 5 mg TZ or placebo. Participants and study personnel were blinded. We assessed TZ target engagement by measuring brain ATP with ³¹P-magnetic resonance spectroscopy (MRS) and whole blood ATP with a luminescence assay. Robust linear regression models compared changes between groups controlling for bas

SUBMITTER: Schultz JL 

PROVIDER: S-EPMC8862665 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature